Prosecution Insights
Last updated: October 02, 2026

Examiner: SHIBUYA, MARK LANCE

Tech Center 1600 • Art Units: 1624 1631 1641 1677 1678

This examiner grants 32% of resolved cases

Analysis

SHIBUYA, MARK LANCE is an examiner in Tech Center 1600 and Art Unit 1624. The data includes 158 resolved cases. The allowance rate is 32.3 percent, which reflects the frequency of grants for applications assigned to this examiner. Practitioners can use the 32.3 percent allowance rate to assess the likelihood of a positive outcome during prosecution. The 158 resolved cases provide a data set for analyzing the examiner's historical patterns in this specific technological area.

The interview lift is 24.9 percent. This metric indicates that the allowance rate is higher when an interview is conducted compared to the baseline rate of 32.3 percent. An interview lift of 24.9 percent suggests that direct communication is an effective strategy for overcoming rejections, particularly given the baseline rate. Practitioners should consider scheduling an interview to clarify technical issues or to negotiate claim scope. This 24.9 percent lift shows a clear benefit to verbal engagement with the examiner.

The median days to allowance is 1341. This number represents the middle point of the time required to reach a grant. A median of 1341 days provides a benchmark for the expected duration of the examination process. The combination of the 32.3 percent allowance rate and the 1341-day pendency defines the current prosecution environment for this examiner. These figures help applicants to manage expectations regarding both the timing and the probability of success.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

32.3%
Allow Rate
-27.7% vs TC avg
184
Total Applications
+24.9%
Interview Lift
1341
Avg Prosecution Days
Based on 158 resolved cases, 2023–2026

Rejection Statute Breakdown

4.2%
§101 Eligibility
18.4%
§102 Novelty
38.4%
§103 Obviousness
27.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17919052 ENHANCED EFFECTS OF GENE-IMMUNOTHERAPY AND IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS Non-Final OA University of Florida Research Foundation, Incorporated
18271911 ADRENERGIC MECHANISMS OF AUDIOGENIC SEIZURE-INDUCED DEATH IN MOUSE MODEL OF SCN8A ENCEPHALOPATHY Non-Final OA University of Virginia Patent Foundation
17870607 RIBOSOME TERMINATION STRUCTURES AND USE THEREOF Non-Final OA RAMOT AT TEL-AVIV UNIVERSITY LTD
18554748 COMPOSITIONS USEFUL FOR TREATING SPINAL AND BULBAR MUSCULAR ATROPHY (SBMA) Non-Final OA The Trustees of the University of Pennsylvania
18317772 METHODS OF TREATING METACHROMATIC LEUKODYSTROPHY Non-Final OA Genzyme Corporation
18001462 3D CULTURE OF MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS Final Rejection MESOBLAST INTERNATIONAL SÁRL

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month